Clinical trial
An Open-Label, Randomized, Parallel Group Study of Patients Treated With Paclitaxel With Standard Dosing Versus Pharmacokinetic Guided Dose Adjustment in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)
NCT01326767 is registered in ClinicalTrials.gov with Central European Society for Anticancer Drug Research as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Randomized, Parallel Group Study of Patients Treated With Paclitaxel With Standard Dosing Versus Pharmacokinetic Guided Dose Adjustment in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)
- Lead sponsor
- Central European Society for Anticancer Drug Research
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2011
- Completion date
- December 31, 2014
- Enrollment
- 366 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.